{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:42:25Z","timestamp":1783730545889,"version":"3.55.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Neurosci."],"DOI":"10.3389\/fncel.2024.1389718","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T12:22:36Z","timestamp":1716553356000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Inhibition of astrocytic glycine transporter-1: friend or foe for ameliorating NMDA receptor hypofunction?"],"prefix":"10.3389","volume":"18","author":[{"given":"Philipp","family":"Singer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin K.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/mp.2008.130","article-title":"Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior","volume":"14","author":"Basu","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1042\/BST0340055","article-title":"Glycine transporters: essential regulators of synaptic transmission","volume":"34","author":"Betz","year":"2006","journal-title":"Biochem. Soc. Trans."},{"key":"B3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","article-title":"Bitopertin in negative symptoms of schizophrenia-results from the phase III FlashLyte and DayLyte studies","volume":"82","author":"Bugarski-Kirola","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/schbul\/16.3.425","article-title":"Schizophrenia: a subcortical neurotransmitter imbalance syndrome?","volume":"16","author":"Carlsson","year":"1990","journal-title":"Schizophr. Bull."},{"key":"B5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13543776.2018.1429408","article-title":"Glycine transporter-1 inhibitors: a patent review (2011-2016)","volume":"28","author":"Cioffi","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"B6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10571-006-9062-8","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell Mol. Neurobiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1176\/appi.ajp.2020.20101481","article-title":"Fifty years of research on schizophrenia: the ascendance of the glutamatergic Synapse","volume":"177","author":"Coyle","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1124\/molpharm.121.000460","article-title":"Metabotropic glutamate receptors as emerging targets for the treatment of schizophrenia","volume":"101","author":"Dogra","year":"2022","journal-title":"Mol. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","article-title":"Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: double-blind, randomised, placebo-controlled phase 2 study","volume":"8","author":"Fleischhacker","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0896-6273(03)00673-1","article-title":"Deletion of the mouse glycine transporter 2 results in a hyperekplexia phenotype and postnatal lethality","volume":"40","author":"Gomeza","year":"2003","journal-title":"Neuron"},{"key":"B11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.brainresbull.2012.12.002","article-title":"Mechanisms of glycine release, which build up synaptic and extrasynaptic glycine levels: the role of synaptic and nonsynaptic glycine transporters","volume":"93","author":"Harsing","year":"2013","journal-title":"Brain Res. Bull"},{"key":"B12","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nrd3893","article-title":"Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence, and pain","volume":"12","author":"Harvey","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1152\/physrev.00049.2005","article-title":"Astrocyte control of synaptic transmission and neurovascular coupling","volume":"86","author":"Haydon","year":"2006","journal-title":"Physiol. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1192\/bjp.169.5.610","article-title":"Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia","volume":"169","author":"Heresco-Levy","year":"","journal-title":"Br. J. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archpsyc.56.1.29","article-title":"Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia","volume":"56","author":"Heresco-Levy","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"B16","first-page":"731","article-title":"Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia","volume":"32","author":"Heresco-Levy","year":"","journal-title":"Psychopharmacol. Bull."},{"key":"B17","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/sj.mp.4001551","article-title":"Glutamate as a therapeutic target in psychiatric disorders","volume":"9","author":"Javitt","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1176\/ajp.151.8.1234","article-title":"Amelioration of negative symptoms in schizophrenia by glycine","volume":"151","author":"Javitt","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/JCP.0000000000000722","article-title":"Neurophysiological effects of bitopertin in schizophrenia","volume":"37","author":"Kantrowitz","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1017\/S1461145709990939","article-title":"A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia","volume":"13","author":"Lane","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1038\/ncomms2779","article-title":"Identity of endogenous NMDAR glycine site agonist in amygdala is determined by synaptic activity level","volume":"4","author":"Li","year":"2013","journal-title":"Nat. Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3109\/15622975.2015.1117654","article-title":"Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial","volume":"18","author":"Lin","year":"2017","journal-title":"World J. Biol. Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13041-017-0293-z","article-title":"Targeting metabotropic glutamate receptors for novel treatments of schizophrenia","volume":"10","author":"Maksymetz","year":"2017","journal-title":"Mol. Brain"},{"key":"B24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00213-004-1792-z","article-title":"Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia","volume":"174","author":"Moghaddam","year":"2004","journal-title":"Psychopharmacology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bcp.2011.02.003","article-title":"Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition","volume":"81","author":"M\u00f6hler","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"20736","DOI":"10.1073\/pnas.1909458116","article-title":"The NMDA receptor activation by d-serine and glycine is controlled by an astrocytic Phgdh-dependent serine shuttle","volume":"116","author":"Neame","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B28","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","article-title":"Glutamate receptor dysfunction and schizophrenia","volume":"52","author":"Olney","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia. J","volume":"33","author":"Olney","year":"1999","journal-title":"Psychiatr. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"742058","DOI":"10.3389\/fpsyt.2021.742058","article-title":"Directly and indirectly targeting the glycine modulatory site to modulate NMDA receptor function to address unmet medical needs of patients with schizophrenia","volume":"12","author":"Pei","year":"2021","journal-title":"Front. Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2533\/chimia.2018.477","article-title":"Glycine transporter type I (GlyT1) inhibitor, bitopertin: a journey from lab to patient","volume":"72","author":"Pinard","year":"2018","journal-title":"Chimia"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1523\/JNEUROSCI.3836-12.2013","article-title":"Neuronal D-serine and glycine release via the Asc-1 transporter regulates NMDA receptor-dependent synaptic activity","volume":"33","author":"Rosenberg","year":"2013","journal-title":"J. Neurosci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","article-title":"Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia","volume":"273","author":"Rosenbrock","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.9740\/mhc.2016.11.266","article-title":"Glycinergic signaling in the human nervous system: an overview of therapeutic drug targets and clinical effects","volume":"6","author":"Schmidt","year":"2016","journal-title":"Ment. Health Clin."},{"key":"B35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jnc.13741","article-title":"Glycine release from astrocytes via functional reversal of GlyT1","volume":"140","author":"Shibasaki","year":"2017","journal-title":"J. Neurochem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.2174\/1381612821666150724100952","article-title":"Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?","volume":"21","author":"Singer","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-013-1611-0","article-title":"A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia","author":"Singer","year":"2015","journal-title":"Cell Tissue Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.neuroscience.2009.03.056","article-title":"Altered mnemonic functions and resistance to N-METHYL-d-Aspartate receptor antagonism by forebrain conditional knockout of glycine transporter 1","volume":"161","author":"Singer","year":"2009","journal-title":"Neuroscience"},{"key":"B39","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1023\/A:1007586314648","article-title":"d-amino acids as putative neurotransmitters; focus on d-serine","volume":"25","author":"Snyder","year":"2000","journal-title":"Neurochem. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.biopsych.2003.09.012","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia","volume":"55","author":"Tsai","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.bbapap.2011.01.001","article-title":"Serine racemase and the serine shuttle between neurons and astrocytes","volume":"1814","author":"Wolosker","year":"2011","journal-title":"Biochim. Biophys. Acta."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1042\/BST20130220","article-title":"The serine shuttle between glia and neurons: implications for neurotransmission and neurodegeneration","volume":"41","author":"Wolosker","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1523\/JNEUROSCI.5120-05.2006","article-title":"Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile","volume":"26","author":"Yee","year":"2006","journal-title":"J. Neurosci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.12740\/PP\/OnlineFirst\/126661","article-title":"Glycine transporters in schizophrenia. A new hope or informational noise?","volume":"56","author":"Zakowicz","year":"2022","journal-title":"Psychiatr. Pol."}],"container-title":["Frontiers in Cellular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fncel.2024.1389718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T12:22:39Z","timestamp":1716553359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fncel.2024.1389718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":45,"alternative-id":["10.3389\/fncel.2024.1389718"],"URL":"https:\/\/doi.org\/10.3389\/fncel.2024.1389718","relation":{},"ISSN":["1662-5102"],"issn-type":[{"value":"1662-5102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,24]]},"article-number":"1389718"}}